Chronic Meningitis
NEJM 385:930-936, Aksamit, A.J., 2021
Treatment of Postural Hypotension
JNNP 65:285-289, Mathias,C.J.&Kimber,J.R., 1998
Recent Advances in the Diagnosis and Management of Cluster Headache
BMJ 376:e059577, Schindler, E. & Burish, M.J., 2022
Alzheimers Disease
Lancet 397:1577-1590, Scheltens, P.,et al, 2021
Mechanisms of Ischemic Stroke in Patients with Cancer
Ann Neurol 90:159-169, Navi, B.B.,et al, 2021
Essential Tremor
NEJM 378:1802-1810, Haubenberger, D.,et al, 2018
Orthostatic Tremor
Neurol 86:458-464, Hassan, A.,et al, 2016
Characteristics of Cryptogenic Stroke in Cancer Patients
Ann Clin Trans Neurol 3:280-287, Gon, Y.,et al, 2016
Imaging Findings of Cerebral Amyloid Angiopathy A�-Related Angiitis (ABRA), and Cerebral Amyloid Angiopathy-Related Inflammation
Medicine 95:e3613, Salvarani, C.,et al, 2016
Clinical Features, Diagnosis, and Treatment of Disseminated Intravascular Coagulation in Adults
UptoDate, Leung, L.L.K., 2015
Amyloid Beta-Related Angiitis - A Case Report and Comprehensive Review of Literature of 94 Cases
Semin Arthritis Rheum 44:86-92, Danve, A.,et al, 2014
Amyloid-Beta Related Angiitis of the Central Nervous System: Case Report and Topic Review
Front Neurol 5:1-4, Nouh, A.,et al, 2014
Degenerative Diseases of the Nervous System, Alzheimer Disease
Adams & Victors Principles of Neurology, Chp 39, pg 1063, Ropper, A.H.,et al, 2014
Stroke and Cancer - A Complicated Relationship
J Neurol Transl Neurosci 2:1039-1051, Dearborn, J.L.,et al, 2014
Sporadic Cerebral Amyloid Angiopathy Revisited: Recent Insights Into Pathophysiology and Clinical Spectrum
JNNP 83:124-137, Charidimou,A.,et al, 2012
Cluster Headache
BMJ 344:e2407, Nesbitt,A.D.,et al, 2012
Evidence-based Guideline Update: Pharmacologic Treatment for Episodic Migraine Prevention in Adults
Neurol 78:1337-1345, Silberstein,S.D.,et al, 2012
Clinical and Biomarker Changes in Dominantly Inherited Alzheimers Disease
NEJM 367:795-804,864, Bateman, R.J.,et al, 2012
Cerebral Amyloid Angiopathy Related Inflammation: Three Case Reports and a Review
JNNP 82:20-26, Chung,K.K.,et al, 2011
Diagnosis and Management of Cerebral Venous Thrombosis: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association
Stroke 42:1158-1192, Saposnik,G.,et al, 2011
Alzheimers Disease
NEJM 362:329-344, Querfurth,H.W. &LaFerla,F.M., 2010
Cerebral Amyloid Angiopathy
UpToDate: May 2010, Greenberg,S.M.,et al, 2010
Multiple Sclerosis Therapeutics: Unexpected Outcomes Clouding Undisputed Successes
Neurol 72:1008-1015, Wiendl,H. &Hohlfeld,R., 2009
The Present Efficacy of Multiple Sclerosis Therapeutics
Neurol 73:984-990, Klawiter,E.,et al, 2009
Paraneoplastic Syndromes Affecting Brain and Cranial Nerves
UpToDate May 2009, Dalmau,J. &Rosenfeld,M., 2009
Disease-Modifying Therapies for Alzheimers: New Drugs on the Horizon
Practical Neurology 7:16-23, Christensen,D.B., 2008
Anti-NMDA-Receptor Encephalitis: Case Series and Analysis of the Effects of Antibodies
Lancet Neurol 7:1091-1098, Dalmau,J.,et al, 2008
Neutralizing Antibodies to Interferon Beta: Assessment of Their Clinical and Radiographic Impact: An Evidence Report
Neurol 68:977-984, Goodin,D.S.,et al, 2007
Clinical Update:Diagnosis and Treatment of Essential Tremor
Lancet 369:1152-1154, Benito-Leon,J&Louis,E.D., 2007
Neutralizing Antibodies to Interferon Beta: Assessment of Their Clinical and Radiographic Impact: An Evidence Report: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
Neurol 69:1552-1553, Sorenson,P.S. &Bertolotto,A., 2007
Stroke as the First Manifestation of Concealed Cancer
J Neurol Sci 258:80-83, Kwon, H.M.,et al, 2007
Neurocardiogenic Syncope
NEJM 352:1004-1010, Grubb, B.P., 2005
Practice Parameter:Therapies for Essential Tremor
Neurol 64:2008-2020, Zesiewicz,T.A.,et al, 2005
Neutralizing Anti-IFN-B Antibodies
Neurol 65:6-8, Giovannoni,G.&Goodman,A., 2005
Interferons in Relapsing Remitting Multiple Sclerosis: A Systematic Review
Lancet 361:545-552, Filippini,G.,et al, 2003
Neuroimaging and Early Diagnosis of Alzheimer Disease: A Look to the Future
Radiology 226:315-336, Petrella,J.R.,et al, 2003
Disease Modifying Therapies in Multiple Sclerosis
Neurol 58:169-178, Goodin,D.S.,et al, 2002
Alzheimer Disease
JAMA 287:2335-2338, Cummings,J.L. &Cole,G., 2002
Disease-Modifying Therapy in Multiple Sclerosis: Strategies for Optimizing Management
The Neurologist 8:227-236, Frohman,E.,et al, 2002
Measurement of Antibodies to Interferon Beta in Patients With Multiple Sclerosis
Arch Neurol 58:1299-1300,1301, Pachner,A.R., 2001
The Significance of Neutralizing Antibodies in Patients With Multiple Sclerosis Treated With Interferon Beta
Arch Neurol 58:1297-1298,1301, Rice,G., 2001
Essential Tremor
NEJM 345:887-891, Louis,E.D., 2001
Multiple Sclerosis
NEJM 343:938-952, Noseworthy,J.H. et al, 2000
Vasovagal Syncope
Ann Int Med 133:714-725, Fenton,A.M.,et al, 2000
Multiple Sclerosis,Therapeutic Update
Arch Neurol 56:277-280, Tselis,A.C.&Lisak,R.P., 1999
Disease-Modifying Drugs for Relapsing-Remitting Multiple Sclerosis and Future Directions for Multiple Sclerosis Therapeutics
Arch Neurol 56:1079-1084, Rudick,R.A., 1999
Treatment Recommendations for Interferon-B in Multiple Sclerosis
JNNP 67:561-566, Polman,C.H.,et al, 1999
Multiple Sclerosis, Side Effects of Interferon Beta Therapy and Their Management
Neurol 53:1622-1627, Walther,E.U.&Hohlfeld,R., 1999
A 29-Year-Old Man with Multiple Sclerosis
JAMA 280:1432-1439, Rudick,R.A., 1998